Last reviewed · How we verify
NP137 DL and RP2D — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
NP137 DL and RP2D (NP137 DL and RP2D) — Centre Leon Berard.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| NP137 DL and RP2D TARGET | NP137 DL and RP2D | Centre Leon Berard | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- NP137 DL and RP2D CI watch — RSS
- NP137 DL and RP2D CI watch — Atom
- NP137 DL and RP2D CI watch — JSON
- NP137 DL and RP2D alone — RSS
Cite this brief
Drug Landscape (2026). NP137 DL and RP2D — Competitive Intelligence Brief. https://druglandscape.com/ci/np137-dl-and-rp2d. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab